Impact of early post-transplant measurable residual disease on
outcomes of patients with relapsed or refractory AML: a post-hoc
analysis of the prospective ASAP trial
Egger-Heidrich, K., Reicherts, C., Bug, G., Wagner-Drouet, E-M., Müller, L.P., Schmid, C., Krause, S.W., Bethge, W., Jost, E., Franke, G-N., Klein, S.A., Niederland, J., Kaufmann, M., Schäfer-Eckart, K., Baldauf, H., Heidenreich, F., Günther, U-P., Visco, I., Schöfl, G., Fuhrmann, M., Stölzel, F., Trost, S., Röllig, C., von Bonin, M., Kunadt, D., Steffen, B., Hauptrock, B., Schliemann, C., Sockel, K., Lang, F., Kriege, O., Schaffrath, J., Serve, H., Mikesch, J-H., Middeke, M., Bornhäuser, M., Schetelig, J., Stelljes, M. on behalf of the Study Alliance Leukemia and the German Cooperative Transplant Study Group.